Development of pro-angiogenic engineered transcription factors for the treatment of cardiovascular disease

Expert Opinion on Investigational Drugs

Volumn 13, Issue 7, 2004, Pages 829-839

  Rebar, Edward J ^a  

^a SANGAMO BIOSCIENCES INC   (United States)

Author keywords

Angiogenesis; Cardiovascular disease; Gene therapy; HIF 1 ; Transcription factor; Vascular endothelial growth factor; Zinc finger

Indexed keywords

ANGIOGENIC FACTOR; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; HELIX LOOP HELIX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SCATTER FACTOR; TRANSCRIPTION FACTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; ZINC FINGER PROTEIN;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DNA SPLICING; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE SEQUENCE; GENE THERAPY; GENETIC ENGINEERING; GENETIC LINKAGE; GENETIC VARIABILITY; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; PROTEIN MOTIF; REVIEW; TRANSCRIPTION INITIATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; GENE THERAPY; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN ENGINEERING; TRANSCRIPTION FACTORS;

EID: 3843087214     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.7.829     Document Type: Review

References (110)

1. Heart Disease and Stroke Statistics - 2003 Update. (2002).
2. MUKHERJEE D, BHATT DL, ROE MT, PATEL V, ELLIS SG: Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am. J. Cardiol. (1999) 94:598-600 (A8).
3. AVILES RJ, ANNEX BH, LEDERMAN RJ: Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2). Br. J. Pharmacol. (2003) 140:637-646.
4. SCOTT R, BLACKSTONE EH, McCARTHY PM et al.: Isolated bypass grafting of the left internal thoracic artery to the left anterior descending coronary artery. late consequences of incomplete revascularization. J. Thorac. Cardiovasc. Surg. (2000) 120:173-184.
5. TAKESHITA S, TSURUMI Y, COUFFINAHL T et al.: Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab. Invest. (1996) 75:487-501.
6. TSURUMI Y, KEARNEY M, CHEN D et al.: Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation (1997) 96:II-382-388.
7. TANIYAMA Y, MORISHITA R, HIRAOKA K et al.: Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation (2001) 104:2344-2350.
8. RISSANEN TT, MARKKANEN JE, ARVE K et al.: Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. Faseb J. (2003) 17:100-102.
9. SMITH RS Jr, LIN KF, AGATA J, CHAO L, CHAO J: Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler. Thromb. Vasc. Biol. (2002) 22:1279-1285.
10. NAMBA T, KOIKE H, MURAKAMI K et al.: Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation (2003) 108:2250-2257.
11. TANIYAMA Y, MORISHITA R, AOKI M et al.: Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. (2001) 8:181-189.
12. LEE LY, PATEL SR, HACKETT NR et al.: Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothetial growth factor 121. Ann. Thorac. Surg. (2000) 69:14-23 (Discussion 23-24).
13. GIORDANO FJ, PING P, McKIRNAN MD et al.: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. (1996) 2:534-539.
14. CROTTOGINI A, MECKERT PC, VERA JANAVEL G et al.: Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. Hum. Gene Ther. (2003) 14:1307-1318.
15. LEOTTA E, PATEJUNAS G, MURPHY G et al.: Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J. Thorac. Cardiovasc. Surg. (2002) 123:1101-1113.
16. GRINES C, RUBANYI GM, KLEIMAN NS, MARROTT P, WATKINS MW: Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am. J. Cardiol. (2003) 92:24N-31N.
17. DIAZ-SANDOVAL LJ, LOSORDO DW: Gene therapy for cardiovascular angiogenesis. Expert Opin. Biol. Ther. (2003) 3:599-616.
18. SIMONS M, WARE JA: Therapeutic angiogenesis in cardiovascular disease. Nat. Rev. Drug Discov. (2003) 2:863-871.
19. RAJAGOPALAN S, MOHLER ER 3rd, LEDERMAN RJ et al.: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a Phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation (2003) 108:1933-1938.
20. HEDMAN M, HARTIKAINEN J, SYVANNE M et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and instent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 107:2677-2683.
21. GRINES CL, WATKINS MW, MAHMARIAN JJ et al.: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. (2003) 42:1339-1347.
22. MAKINEN K, MANNINEN H, HEDMAN M et al.: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded Phase II study. Mol. Ther. (2002) 6:127-133.
23. HENRY TD, ANNEX BH, McKENDALL GR et al.: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation (2003) 107:1359-1365.
24. LEDERMAN RJ, MENDELSOHN FO, ANDERSON RD et al.: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet (2002) 359:2053-2058.
25. SIMONS M, ANNEX BH, LAHAM RJ et al.: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation (2002) 105:788-793.
26. LAHAM RJ, SELLKE FW, EDELMAN ER et al.: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a Phase I randomized, double-blind, placebo-controlled trial. Circulation (1999) 100:1865-1871.
27. RUEL M, LAHAM RJ, PARKER JA et al.: Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. (2002) 124:28-34.
28. RUEL M, SELLKE FW: Angiogenic protein therapy. Semin. Thorac. Cardiovasc. Surg. (2003) 15:222-235.
29. JANG JJ, HO HK, KWAN HH, FAJARDO LF, COOKE JP: Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation (2000) 102:1414-1419.
30. DUAN J, MUROHARA T, IKEDA H et al.: Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation (2000) 102:III370-376.
31. SASAKI K, DUAN J, MUROHARA T et al.: Rescue of hypercholesterolemia-related impairment of angiogenesis by oral folate supplementation. J. Am. Coll. Cardiol. (2003) 42:364-372.
32. VAN BELLE E, RIVARD A, CHEN D et al.: Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation (1997) 96:2667-2674.
33. MICHAUD SE, MENARD C, GUY LG, GENNARO G, RIVARD A: Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1α/VEGF pathway. Faseb J. (2003) 17:1150-1152.
34. RUEL M, WU GF, KHAN TA et al.: Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation (2003) 108(Suppl. 1):II335-II340.
35. SHYU KG, CHANG H, ISNER JM: Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci. (2003) 73:563-579.
36. RICHARDSON TP, PETERS MC, ENNETT AB, MOONEY DJ: Polymeric system for dual growth factor delivery. Nat. Biotechnol. (2001) 19:1029-1034.
37. ASAHARA T, BAUTERS C, ZHENG LP et al.: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation (1995) 92:II365-371.
38. CHAE JK, KIM I, LIM ST et al.: Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2573-2578.
39. KHAN TA, SELLKE FW, LAHAM RJ: Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. (2003) 10:285-291.
40. SIMONS M, BONOW RO, CHRONOS NA et al.: Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation (2000) 102:E73-E86.
41. JAIN RK: Molecular regulation of vessel maturation. Nat. Med. (2003) 9:685-693.
42. CARMELIET P: Angiogenesis in health and disease. Nat. Med. (2003) 9:653-660.
43. FERRARA N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. (1999) 56:794-814.
44. TISCHER E, MITCHELL R, HARTMAN T et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. (1991) 266:11947-11954.
45. POLTORAK Z, COHEN T, SIVAN R et al.: VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. (1997) 272:7151-7158.
46. LANGE T, GUTTMANN-RAVIV N, BARUCH L, MACHLUF M, NEUFELD G: VEGF162, a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells. J. Biol. Chem. (2003) 278:17164-17169.
47. NEUFELD G, COHEN T, GITAY-GOREN H et al.: Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev. (1996) 15:153-158.
48. GRUNSTEIN J, MASBAD JJ, HICKEY R, GIORDANO F, JOHNSON RS: Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol. Cell Biol. (2000) 20:7282-7291.
49. WHITLOCK PR, HACKETT NR, LEOPOLD PL, ROSENGART TK, CRYSTAL RG: Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol. Ther. (2004) 9:67-75.
50. DENT CL, LAU G, LIANG Y, CASE CC, PABO CO: Transcriptional activation of the endogenous VEGF gene by small molecule regulated engineered transcription factors. American Society of Gene Therapy.. Washington DC, USA (2003) (Abstract 786).
51. ABRUZZESE RV, GODIN D, BURCIN M et al.: Ligand-dependent regulation of plasmid-based transgene expression in vivo. Hum. Gene Ther. (1999) 10:1499-1507.
52. POLLOCK R, GIEL M, LINHER K, CLACKSON T: Regulation of endogenous gene expression with a small-molecule dimerizer. Nat. Biotechnol. (2002) 20:729-733.
53. FRANKEL AD, KIM PS: Modular structure of transcription factors: implications for gene regulation. Cell (1991) 65:717-719.
54. WILLS KN, MANO T, AVANZINI JB et al.: Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle α-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Ther. (2001) 8:1847-1854.
55. YOU XM, MUNGRUE IN, KALAIR W et al.: Conditional expression of a dominant-negative c-Myb in vascular smooth muscle cells inhibits arterial remodeling after injury. Circ. Res. (2003) 92:314-321.
56. 2 homeostasis by hypoxia-inducible factor 1. Ann. Rev. Cell. Dev. Biol. (1999) 15:551-578.
57. 2 sensing. Science (2001) 292:464-468.
58. 2-regulated prolyl hydroxylation. Science (2001) 292:468-472.
59. BRUICK RK, McKNIGHT SL: A conserved family of prolyl-4-hydroxylases that modify HIF. Science (2001) 294:1337-1340.
60. EPSTEIN AC, GLEADLE JM, McNEILL LA et al.: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107:43-54.
61. LANDO D, PEET DJ, WHELAN DA, GORMAN JJ, WHITELAW ML: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (2002) 295:858-861.
62. VINCENT KA, SHYU KG, LUO Y et al.: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α /VP16 hybrid transcription factor. Circulation (2000) 102:2255-2261.
63. KELLY BD, HACKETT SF, HIROTA K et al.: Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. (2003) 93:1074-1081.
64. SADOWSKI I, MA J, TRIEZENBERG S, PTASHNE M: GAL4-VP16 is an unusually potent transcriptional activator. Nature (1988) 335:563-564.
65. TRIEZENBERG SJ, KINGSBURY RC, MCKNIGHT SL: Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression. Genes Dev. (1988) 2:718-729.
66. LIU LX, LU H, LUO Y et al.: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (2002) 291:908-914.
67. BELANGER AJ, LU H, DATE T et al.: Hypoxia up-regulates expression of peroxisome proliferator-activated receptor gamma angiopoietin-related gene (PGAR) in cardiomyocytes: role of hypoxia inducible factor 1alpha. J. Mol. Cell. Cardiol. (2002) 34:765-774.
68. YAMAKAWA M, LIU LX, DATE T et al.: Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ. Res. (2003) 93:664-673.
69. JLANG C, LU H, VINCENT KA et al.: Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α. Physiol. Genomics (2002) 8:23-32.
70. SHYU KG, WANG MT, WANG BW et al.: Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. (2002) 54:576-583.
71. RAJAGOPALAN S, DEITCHER S, OLIN J et al.: Harnessing the response to hypoxia: use of a constitutively active hypoxia-inducible factor 1-a transgene in no-option critical limb ischemia patients. American Heart Association Scientific Sessions. Orlando, USA (2003) (Abstract 2034).
72. MILLER J, McLACHLAN AD, KLUG A: Repetitive zinc-binding domains in the protein transcription Factor IIIA from Xenopus oocytes. EMBO J. (1985) 4:1609-1614.
73. BROWN RS, SANDER C, ARGOS P: The primary structure of transcription factor TFIIIA has 12 consecutive repeats. FEBS Lett. (1985) 186:271-274.
74. PABO CO, PEISACH E, GRANT RA: Design and selection of novel Cys2His2 zinc finger proteins. Ann. Rev. Biochem. (2001) 70:313-340.
75. SEEMAN NC, ROSENBERG JM, RICH A: Sequence-specific recognition of double helical nucleic acids by proteins. Proc. Natl. Acad. Sci. USA (1976) 73:804-808.
76. CHRISTY B, NATHANS D: DNA binding site of the growth factor-inducible protein Zif268. Proc. Natl. Acad. Sci. USA (1989) 86:8737-8741.
77. PAVLETICH NP, PABO CO: Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science (1991) 252:809-817.
78. DESJARLAIS JR, BERG JM: Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins. Proc. Natl. Acad. Sci. USA (1993) 90:2256-2260.
79. LIU Q, XIA Z, ZHONG X, CASE CC: Validated zinc finger protein designs for all 16 GNN DNA triplet rargets. J. Biol. Chem. (2002) 277:3850-3856.
80. BAE KH, KWON YD, SHIN HC et al.: Human zinc fingers as building blocks in the construction of artificial transcription factors. Nat. Biotechnol. (2003) 21:275-280.
81. REBAR EJ, PABO CO: Zinc finger phage: affinity selection of fingers with new DNA-binding specificities. Science (1994) 263:671-673.
82. REBAR EJ, GREISMAN RA, PABO CO: Phage display methods for selecting zinc finger proteins with novel DNA- binding specificities. Methods Enzymol. (1996) 267:129-149.
83. JAMIESON AC, KIM SH, WELLS JA: In vitro selection of zinc fingers with altered DNA-binding specificity. Biochemistry (1994) 33:5689-5695.
84. CHOO Y, KLUG A: Toward a code for the interactions of zinc fingers with DNA: selection of randomized fingers displayed on phage. Proc. Natl. Acad. Sci. USA (1994) 91:11163-11167.
85. JOUNG JK, RAMM EI, PABO CO: A bacterial two-hybrid selection system for studying protein-DNA and protein-protein interactions. Proc. Natl. Acad. Sci. USA (2000) 97:7382-7387.
86. SEGAL DJ, DREIER B, BEERLI RR, BARBAS CF 3rd: Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences. Proc. Natl. Acad. Sci. USA (1999) 96:2758-2763.
87. DREIER B, BEERLI RR, SEGAL DJ, FLIPPIN JD, BARBAS CF 3rd: Development of zinc finger domains for recognition of the 5′ -ANN-3′ family of DNA sequences and their use in the construction of artificial transcription factors. J. Biol. Chem. (2001) 276:29466-29478.
88. GREISMAN HA, PABO CO: A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. Science (1997) 275:657-661.
89. ISALAN M, KLUG A, CHOO Y: A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat. Biotechnol. (2001) 19:656-660.
90. LIU PQ, REBAR EJ, ZHANG L et al.: Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J. Biol. Chem. (2001) 276:11323-11334.
91. REBAR EJ, HUANG Y, HICKEY R et al.: Induction of angiogenesis in a mouse model using engineered transcription factors. Nat. Med. (2002) 8:1427-1432.
92. SNOWDEN AW, ZHANG L, URNOV F et al.: Repression of vascular endothelial growth factor A in glioblastoma cells using engineered zinc finger transcription factors. Cancer Res. (2003) 63:8968-8976.
93. BEERLI RR, DREIER B, BARBAS CF 3rd: Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA (2000) 97:1495-1500.
94. ZHANG L, SPRATT SK, LIU Q et al.: Synthetic zinc finger transcription factor action at an endogenous chromosomal site. Activation of the human erythropoietin gene. J. Biol. Chem. (2000) 275:33850-33860.
95. BARTSEVICH W, MILLER JC, CASE CC, PABO CO: Engineered zinc finger proteins for controlling stem cell fate. Stem Cells (2003) 21:632-637.
96. FALKE D, FISHER M, YE D, JULIANO RL: Design of artificial transcription factors to selectively regulate the pro-apoptotic bar gene. Nucleic Acids Res. (2003) 31:e10.
97. BARTSEVICH VV, JULIANO RL: Regulation of the MDR1 gene by transcriptional repressors selected using peptide combinatorial libraries. Mol. Pharmacol. (2000) 58:1-10.
98. JOUVENOT Y, GINJALA V, ZHANG L et al.: Targeted regulation of imprinted genes by synthetic zinc-finger transcription factors. Gene Ther. (2003) 10:513-522.
99. TAN S, GUSCHIN D, DAVALOS A et al.: Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc. Natl. Acad. Sci. USA (2003) 100:11997-12002.
100. BLANCAFORT P, MAGNENAT L, BARBAS CF 3rd: Scanning the human genome with combinatorial transcription factor libraries. Nat. Biotechnol. (2003) 21:269-274.
101. REN D, COLLINGWOOD TN, REBAR EJ, WOLFFE AP, CAMP HS: PPARγ knockdown by engineered transcription factors: erogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev. (2002) 16:27-32.
102. LIANG Y, LI XY, REBAR EJ et al.: Activation of vascular endothelial growth factor A transcription in tumorigenic glioblastoma cell lines by an enhancer with cell type-specific DNase I accessibility. J. Biol. Chem. (2002) 277:20087-20094.
103. REBAR EJ, ZHANG L, DENT C et al.: Robust activation of vascular endothelial growth factor a using designed zinc finger protein transcription factors. American Society ef Gene Therapy. Washington DC, USA (2003) (Abstract 1192).
104. JOHNSTONE B, VENSTROM K, ZHANG L et al.: Induction of angiogenesis in rat skeletal muscle using a designed zinc finger protein transcriptional activator targeted to vascular endothelial growth factor A (VEGF-A). American Society of Gene Therapy. Washington DC, USA (2003) (Abstract 603).
105. DAI Q, HUANG J, KLITZMAN B et al.: A genetically engineered plasmid encoding a zinc finger vegf-activating transcription factor induces angiogenesis in the rabbits with hind-limb ischemia. American Society of Gene Therapy. Washington DC, USA (2003) (Abstract 855).
106. OZAWA CR, BANFI A, GLAZER NL et al.: Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. (2004) 113:516-527.
107. CHAPMAN-SMITH A, LUTWYCHE JK, WHITELAW ML: Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators. J. Biol. Chem. (2004) 279:5353-5362.
108. JIANG BH, ZHENG JZ, LEUNG SW, ROE R, SEMENZA GL: Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. (1997) 272:19253-19260.
109. ELROD-ERICKSON M, ROULD MA. NEKLUDOVA L, RABO CO: Zif268 protein-DNA complex refined at 1.6 A: a model system for understanding zinc finger-DNA interactions. Structure (1996) 4:1171-1180.
110. SCHAAL TD, HOLMES MC, REBAR EJ, CASE CC: Novel approaches to controlling transcription. Genet. Eng. (NY) (2002) 24:137-178.